Bristol Myers Squibb Expected to Report Lower 4Q Revenue -- Earnings Preview

Dow Jones

Feb 05

By Nicholas G. Miller

Bristol Myers Squibb is scheduled to report its fourth-quarter results before the market opens Thursday. Here is what you need to know.

PROFIT: Analysts polled by FactSet expect the company to record net income of $1.93 billion, up from $72 million the year before.

ADJUSTED EARNINGS: Stripping out one-time items, the company is expected to report earnings of $1.23 a share, down from $1.67 a share the year prior.

REVENUE: Wall Street is forecasting revenue of $12.28 billion, down from $12.34 billion.

The stock is up 26% over the past three months and was recently trading at $57.66.

WHAT TO WATCH:

--The company is losing exclusivity of some of its key legacy drugs and investors will be listening for commentary about how much that will hurt Bristol Myers Squibb's revenue and how the company plans to offset the sales declines.

--Revenue from the company's Eliquis blood thinner will be pressured in 2026 due to Medicare price negotiations that recently went into effect. Investors will want to hear about how much that lower price will hit overall revenue.

--The company has been seeing strong growth from its immuno-oncology drugs Breyanzi, Reblozyl and Camzyos. Investors will be watching closely for signs that growth is continuing and will be able to offset declines in the company's legacy portfolio.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

February 04, 2026 12:48 ET (17:48 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609394894"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609394894\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609394894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 01:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609394894","market":"hk","top_or_hot":-1,"title":"Bristol Myers Squibb Expected to Report Lower 4Q Revenue -- Earnings Preview","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Bristol Myers Squibb is scheduled to report its fourth-quarter results before the market opens Thursday. Here is what you need to know. \n</p>\n<p>\n  PROFIT: Analysts polled by FactSet expect the company to record net income of $1.93 billion, up from $72 million the year before. \n</p>\n<p>\n  ADJUSTED EARNINGS: Stripping out one-time items, the company is expected to report earnings of $1.23 a share, down from $1.67 a share the year prior. \n</p>\n<p>\n  REVENUE: Wall Street is forecasting revenue of $12.28 billion, down from $12.34 billion. \n</p>\n<p>\n  The stock is up 26% over the past three months and was recently trading at $57.66. \n</p>\n<p>\n  WHAT TO WATCH: \n</p>\n<p>\n  --The company is losing exclusivity of some of its key legacy drugs and investors will be listening for commentary about how much that will hurt Bristol Myers Squibb's revenue and how the company plans to offset the sales declines. \n</p>\n<p>\n  --Revenue from the company's Eliquis blood thinner will be pressured in 2026 due to Medicare price negotiations that recently went into effect. Investors will want to hear about how much that lower price will hit overall revenue. \n</p>\n<p>\n  --The company has been seeing strong growth from its immuno-oncology drugs Breyanzi, Reblozyl and Camzyos. Investors will be watching closely for signs that growth is continuing and will be able to offset declines in the company's legacy portfolio. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 04, 2026 12:48 ET (17:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb Expected to Report Lower 4Q Revenue -- Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb Expected to Report Lower 4Q Revenue -- Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-05 01:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Bristol Myers Squibb is scheduled to report its fourth-quarter results before the market opens Thursday. Here is what you need to know. \n</p>\n<p>\n  PROFIT: Analysts polled by FactSet expect the company to record net income of $1.93 billion, up from $72 million the year before. \n</p>\n<p>\n  ADJUSTED EARNINGS: Stripping out one-time items, the company is expected to report earnings of $1.23 a share, down from $1.67 a share the year prior. \n</p>\n<p>\n  REVENUE: Wall Street is forecasting revenue of $12.28 billion, down from $12.34 billion. \n</p>\n<p>\n  The stock is up 26% over the past three months and was recently trading at $57.66. \n</p>\n<p>\n  WHAT TO WATCH: \n</p>\n<p>\n  --The company is losing exclusivity of some of its key legacy drugs and investors will be listening for commentary about how much that will hurt Bristol Myers Squibb's revenue and how the company plans to offset the sales declines. \n</p>\n<p>\n  --Revenue from the company's Eliquis blood thinner will be pressured in 2026 due to Medicare price negotiations that recently went into effect. Investors will want to hear about how much that lower price will hit overall revenue. \n</p>\n<p>\n  --The company has been seeing strong growth from its immuno-oncology drugs Breyanzi, Reblozyl and Camzyos. Investors will be watching closely for signs that growth is continuing and will be able to offset declines in the company's legacy portfolio. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 04, 2026 12:48 ET (17:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMY","symbol_name":"施贵宝","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2609394894","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609394894","pubTimestamp":1770227280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Bristol Myers Squibb is scheduled to report its fourth-quarter results before the market opens Thursday. Here is what you need to know.PROFIT: Analysts polled by FactSet expect the company to record net income of $1.93 billion, up from $72 million the year before.ADJUSTED EARNINGS: Stripping out one-time items, the company is expected to report earnings of $1.23 a share, down from $1.67 a share the year prior.REVENUE: Wall Street is forecasting revenue of $12.28 billion, down from $12.34 billion.The stock is up 26% over the past three months and was recently trading at $57.66.--The company is losing exclusivity of some of its key legacy drugs and investors will be listening for commentary about how much that will hurt Bristol Myers Squibb's revenue and how the company plans to offset the sales declines.--Revenue from the company's Eliquis blood thinner will be pressured in 2026 due to Medicare price negotiations that recently went into effect. Investors will want to hear about how much","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BMY":"施贵宝"},"translate_title":"百时美施贵宝预计第四季度收入下降——收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Bristol Myers Squibb is scheduled to report its fourth-quarter results before the market opens Thursday. Here is what you need to know. \n\n\n  PROFIT: Analysts polled by FactSet expect the company to record net income of $1.93 billion, up from $72 million the year before. \n\n\n  ADJUSTED EARNINGS: Stripping out one-time items, the company is expected to report earnings of $1.23 a share, down from $1.67 a share the year prior. \n\n\n  REVENUE: Wall Street is forecasting revenue of $12.28 billion, down from $12.34 billion. \n\n\n  The stock is up 26% over the past three months and was recently trading at $57.66. \n\n\n  WHAT TO WATCH: \n\n\n  --The company is losing exclusivity of some of its key legacy drugs and investors will be listening for commentary about how much that will hurt Bristol Myers Squibb's revenue and how the company plans to offset the sales declines. \n\n\n  --Revenue from the company's Eliquis blood thinner will be pressured in 2026 due to Medicare price negotiations that recently went into effect. Investors will want to hear about how much that lower price will hit overall revenue. \n\n\n  --The company has been seeing strong growth from its immuno-oncology drugs Breyanzi, Reblozyl and Camzyos. Investors will be watching closely for signs that growth is continuing and will be able to offset declines in the company's legacy portfolio. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2026 12:48 ET (17:48 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}